Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial

Overview of attention for article published in HemaSphere, August 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter: 4 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 27 Mendeley

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 8,100 followers.

While the primary endpoint of this #Phase3Trial to eval efficacy + safety of volasertib + LDAC was not met, results may help to inform development of other #Plk1 inhibitors. Read more 👉https://t.co/YWb0pTX4sb #leusm #AML https://t.co/QwSkFDsFPL

RT @Hemasphere_EHA: Insights about #volasertib use in older patients with #AML. While the primary endpoint of this #Phase3Trial to eval eff…

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Random… https://t.co/rNcOJkA4WU #hvhebron #onco [Text complet]

Insights about #volasertib use in older patients with #AML. While the primary endpoint of this #Phase3Trial to eval efficacy + safety of volasertib + LDAC was not met, results may help to inform development of other #Plk1 inhibitors. Read more 👉https://t…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.